메뉴 건너뛰기




Volumn 19, Issue 3, 2013, Pages 501-511

High expression of the "A disintegrin and metalloprotease" 19 (ADAM19), a sheddase for TNF-a in the mucosa of patients with inflammatory bowel diseases

Author keywords

ADAM19; Colitis; Inflammatory bowel disease; TNF a

Indexed keywords

A DISINTEGRIN AND METALLOPROTEASE 10; A DISINTEGRIN AND METALLOPROTEASE 19; A DISINTEGRIN AND METALLOPROTEASE 9; ADAM PROTEIN; INFLIXIMAB; INTERLEUKIN 21; INTERLEUKIN 6; MESALAZINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

EID: 84876368553     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31828028e8     Document Type: Article
Times cited : (20)

References (44)
  • 1
    • 70949107842 scopus 로고    scopus 로고
    • Inflammatory bowel disease
    • Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.
    • (2009) N Engl J Med , vol.361 , pp. 2066-2078
    • Abraham, C.1    Cho, J.H.2
  • 2
    • 0142053206 scopus 로고    scopus 로고
    • The immunological and genetic basis of inflammatory bowel disease
    • Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
    • (2003) Nat Rev Immunol , vol.3 , pp. 521-533
    • Bouma, G.1    Strober, W.2
  • 3
    • 33847381116 scopus 로고    scopus 로고
    • The fundamental basis of inflammatory bowel disease
    • Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514-521.
    • (2007) J Clin Invest , vol.117 , pp. 514-521
    • Strober, W.1    Fuss, I.2    Mannon, P.3
  • 5
    • 0025779160 scopus 로고
    • Tumor necrosis factor, new insights into the molecular mechanisms of its multiple actions
    • Vilcek J, Lee TH. Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem. 1991;266:7313-7316.
    • (1991) J Biol Chem , vol.266 , pp. 7313-7316
    • Vilcek, J.1    Lee, T.H.2
  • 6
    • 19644375686 scopus 로고    scopus 로고
    • Molecular mechanism of TNF signaling and beyond
    • Liu ZG. Molecular mechanism of TNF signaling and beyond. Cell Res. 2005;15:24-27.
    • (2005) Cell Res , vol.15 , pp. 24-27
    • Liu, Z.G.1
  • 7
    • 0032833517 scopus 로고    scopus 로고
    • Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
    • Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
    • (1999) Gastroenterology , vol.117 , pp. 761-769
    • Rutgeerts, P.1    D'Haens, G.2    Targan, S.3
  • 8
    • 0037018761 scopus 로고    scopus 로고
    • Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial
    • Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
    • (2002) Lancet , vol.359 , pp. 1541-1549
    • Hanauer, S.B.1    Feagan, B.G.2    Lichtenstein, G.R.3
  • 9
    • 28844473957 scopus 로고    scopus 로고
    • Infliximab for induction and maintenance therapy for ulcerative colitis
    • Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
    • (2005) N Engl J Med , vol.353 , pp. 2462-2476
    • Rutgeerts, P.1    Sandborn, W.J.2    Feagan, B.G.3
  • 10
    • 33846242958 scopus 로고    scopus 로고
    • Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
    • Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
    • (2007) Gastroenterology , vol.132 , pp. 52-65
    • Colombel, J.F.1    Sandborn, W.J.2    Rutgeerts, P.3
  • 11
    • 0030954732 scopus 로고    scopus 로고
    • A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
    • Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
    • (1997) N Engl J Med , vol.337 , pp. 1029-1035
    • Targan, S.R.1    Hanauer, S.B.2    Van Deventer, S.J.3
  • 12
    • 62949219864 scopus 로고    scopus 로고
    • Biological therapies for inflammatory bowel diseases
    • Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009;136:1182-1197.
    • (2009) Gastroenterology , vol.136 , pp. 1182-1197
    • Rutgeerts, P.1    Vermeire, S.2    Van Assche, G.3
  • 13
    • 62049083383 scopus 로고    scopus 로고
    • Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review
    • Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104:760-767.
    • (2009) Am J Gastroenterol , vol.104 , pp. 760-767
    • Gisbert, J.P.1    Panes, J.2
  • 14
    • 63849251824 scopus 로고    scopus 로고
    • Long-term safety of infliximab for the treatment of inflammatory bowel disease: A single-centre cohort study
    • Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501-508.
    • (2009) Gut , vol.58 , pp. 501-508
    • Fidder, H.1    Schnitzler, F.2    Ferrante, M.3
  • 15
    • 0035007746 scopus 로고    scopus 로고
    • Reactivation tuberculosis in a patient with anti-TNF-alpha treatment
    • Nunez Martinez O, Ripoll Noiseux C, Carneros Martin JA, et al. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol. 2001;96:1665-1666.
    • (2001) Am J Gastroenterol , vol.96 , pp. 1665-1666
    • Nunez, M.O.1    Ripoll, N.C.2    Carneros, M.J.A.3
  • 16
    • 67650430007 scopus 로고    scopus 로고
    • Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections
    • Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30:253-264.
    • (2009) Aliment Pharmacol Ther , vol.30 , pp. 253-264
    • Schneeweiss, S.1    Korzenik, J.2    Solomon, D.H.3
  • 17
    • 32044451548 scopus 로고    scopus 로고
    • Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial
    • quiz 591
    • Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
    • (2006) Gastroenterology , vol.130 , pp. 323-333
    • Hanauer, S.B.1    Sandborn, W.J.2    Rutgeerts, P.3
  • 18
    • 0026461349 scopus 로고
    • Genomic structure, induction, and production of TNF-alpha
    • Spriggs DR, Deutsch S, Kufe DW. Genomic structure, induction, and production of TNF-alpha. Immunol Ser. 1992;56:3-34.
    • (1992) Immunol Ser , vol.56 , pp. 3-34
    • Spriggs, D.R.1    Deutsch, S.2    Kufe, D.W.3
  • 19
    • 0024281428 scopus 로고
    • A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF
    • Kriegler M, Perez C, DeFay K, et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988;53:45-53.
    • (1988) Cell , vol.53 , pp. 45-53
    • Kriegler, M.1    Perez, C.2    Defay, K.3
  • 20
    • 0028483534 scopus 로고
    • Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor
    • McGeehan GM, Becherer JD, Bast RC Jr, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature. 1994;370:558-561.
    • (1994) Nature , vol.370 , pp. 558-561
    • McGeehan, G.M.1    Becherer, J.D.2    Bast Jr., R.C.3
  • 21
    • 8044250278 scopus 로고    scopus 로고
    • Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha
    • Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997;385:733-736.
    • (1997) Nature , vol.385 , pp. 733-736
    • Moss, M.L.1    Jin, S.L.2    Milla, M.E.3
  • 22
    • 0036288520 scopus 로고    scopus 로고
    • Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease
    • Brynskov J, Foegh P, Pedersen G, et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut. 2002;51:37-43.
    • (2002) Gut , vol.51 , pp. 37-43
    • Brynskov, J.1    Foegh, P.2    Pedersen, G.3
  • 23
    • 0035931044 scopus 로고    scopus 로고
    • Implication of TNF-alpha convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis
    • Colon AL, Menchen LA, Hurtado O, et al. Implication of TNF-alpha convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis. Cytokine. 2001;16:220-226.
    • (2001) Cytokine , vol.16 , pp. 220-226
    • Colon, A.L.1    Menchen, L.A.2    Hurtado, O.3
  • 24
    • 5644290647 scopus 로고    scopus 로고
    • Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17)
    • Zheng Y, Saftig P, Hartmann D, et al. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem. 2004;279:42898-42906.
    • (2004) J Biol Chem , vol.279 , pp. 42898-42906
    • Zheng, Y.1    Saftig, P.2    Hartmann, D.3
  • 25
    • 4744375545 scopus 로고    scopus 로고
    • Development and validation of a new, simplified endoscopic activity score for Crohn's disease: The SES-CD
    • Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512.
    • (2004) Gastrointest Endosc , vol.60 , pp. 505-512
    • Daperno, M.1    D'Haens, G.2    Van Assche, G.3
  • 26
    • 0023521441 scopus 로고
    • Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study
    • Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
    • (1987) N Engl J Med , vol.317 , pp. 1625-1629
    • Schroeder, K.W.1    Tremaine, W.J.2    Ilstrup, D.M.3
  • 27
    • 0034894059 scopus 로고    scopus 로고
    • Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease
    • Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601-609.
    • (2001) J Clin Invest , vol.108 , pp. 601-609
    • Monteleone, G.1    Kumberova, A.2    Croft, N.M.3
  • 28
    • 0037073443 scopus 로고    scopus 로고
    • Autolytic processing at Glu586-Ser587 within the cysteine-rich domain of human adamalysin 19/disintegrinmetalloproteinase 19 is necessary for its proteolytic activity
    • Kang T, Park HI, Suh Y, et al. Autolytic processing at Glu586-Ser587 within the cysteine-rich domain of human adamalysin 19/ disintegrinmetalloproteinase 19 is necessary for its proteolytic activity. J Biol Chem. 2002;277:48514-48522.
    • (2002) J Biol Chem , vol.277 , pp. 48514-48522
    • Kang, T.1    Park, H.I.2    Suh, Y.3
  • 29
    • 0027451455 scopus 로고
    • Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
    • Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993;94:174-181.
    • (1993) Clin Exp Immunol , vol.94 , pp. 174-181
    • Reinecker, H.C.1    Steffen, M.2    Witthoeft, T.3
  • 30
    • 0033125226 scopus 로고    scopus 로고
    • Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
    • Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-133.
    • (1999) Inflamm Bowel Dis , vol.5 , pp. 119-133
    • Sandborn, W.J.1    Hanauer, S.B.2
  • 31
    • 69249159918 scopus 로고    scopus 로고
    • ADAM19/adamalysin 19 structure, function, and role as a putative target in tumors and inflammatory diseases
    • Qi B, Newcomer RG, Sang QX. ADAM19/adamalysin 19 structure, function, and role as a putative target in tumors and inflammatory diseases. Curr Pharm Des. 2009;15:2336-2348.
    • (2009) Curr Pharm des , vol.15 , pp. 2336-2348
    • Qi, B.1    Newcomer, R.G.2    Sang, Q.X.3
  • 32
    • 0037067764 scopus 로고    scopus 로고
    • Intracellular activation of human adamalysin 19/disintegrin and metalloproteinase 19 by furin occurs via one of the two consecutive recognition sites
    • Kang T, Zhao YG, Pei D, et al. Intracellular activation of human adamalysin 19/disintegrin and metalloproteinase 19 by furin occurs via one of the two consecutive recognition sites. J Biol Chem. 2002; 277:25583-25591.
    • (2002) J Biol Chem , vol.277 , pp. 25583-25591
    • Kang, T.1    Zhao, Y.G.2    Pei, D.3
  • 33
    • 0034643292 scopus 로고    scopus 로고
    • Meltrin beta (ADAM19) gene: Cloning, mapping, and analysis of the regulatory region
    • Kurohara K, Matsuda Y, Nagabukuro A, et al. Meltrin beta (ADAM19) gene: cloning, mapping, and analysis of the regulatory region. Biochem Biophys Res Commun. 2000;270:522-527.
    • (2000) Biochem Biophys Res Commun , vol.270 , pp. 522-527
    • Kurohara, K.1    Matsuda, Y.2    Nagabukuro, A.3
  • 34
    • 0034815337 scopus 로고    scopus 로고
    • Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta
    • Wei P, Zhao YG, Zhuang L, et al. Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta. Biochem Biophys Res Commun. 2001;280:744-755.
    • (2001) Biochem Biophys Res Commun , vol.280 , pp. 744-755
    • Wei, P.1    Zhao, Y.G.2    Zhuang, L.3
  • 35
    • 77953289538 scopus 로고    scopus 로고
    • ADAM19 autolysis is activated by LPS and promotes non-classical secretion of cysteine-rich protein 2
    • Tanabe C, Hotoda N, Sasagawa N, et al. ADAM19 autolysis is activated by LPS and promotes non-classical secretion of cysteine-rich protein 2. Biochem Biophys Res Commun. 2010;396:927-932.
    • (2010) Biochem Biophys Res Commun , vol.396 , pp. 927-932
    • Tanabe, C.1    Hotoda, N.2    Sasagawa, N.3
  • 36
    • 22144454605 scopus 로고    scopus 로고
    • Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2
    • Horiuchi K, Zhou HM, Kelly K, et al. Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2. Dev Biol. 2005;283:459-471.
    • (2005) Dev Biol , vol.283 , pp. 459-471
    • Horiuchi, K.1    Zhou, H.M.2    Kelly, K.3
  • 37
    • 0035937787 scopus 로고    scopus 로고
    • Roles of meltrin beta/ADAM19 in the processing of neuregulin
    • Shirakabe K, Wakatsuki S, Kurisaki T, et al. Roles of Meltrin beta/ADAM19 in the processing of neuregulin. J Biol Chem. 2001;276:9352-9358.
    • (2001) J Biol Chem , vol.276 , pp. 9352-9358
    • Shirakabe, K.1    Wakatsuki, S.2    Kurisaki, T.3
  • 38
    • 0346851877 scopus 로고    scopus 로고
    • Inverse regulation of the ADAM-family members, decysin and MADDAM/ADAM19 during monocyte differentiation
    • Fritsche J, Muller A, Hausmann M, et al. Inverse regulation of the ADAM-family members, decysin and MADDAM/ADAM19 during monocyte differentiation. Immunology. 2003;110:450-457.
    • (2003) Immunology , vol.110 , pp. 450-457
    • Fritsche, J.1    Muller, A.2    Hausmann, M.3
  • 39
    • 33748946027 scopus 로고    scopus 로고
    • ADAM19 expression in human nephrogenesis and renal disease: Associations with clinical and structural deterioration
    • Melenhorst WB, van den Heuvel MC, Timmer A, et al. ADAM19 expression in human nephrogenesis and renal disease: associations with clinical and structural deterioration. Kidney Int. 2006;70:1269-1278.
    • (2006) Kidney Int , vol.70 , pp. 1269-1278
    • Melenhorst, W.B.1    Van Den Heuvel, M.C.2    Timmer, A.3
  • 41
    • 3242799873 scopus 로고    scopus 로고
    • Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome
    • Roemer A, Schwettmann L, Jung M, et al. Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncol Rep. 2004;11:529-536.
    • (2004) Oncol Rep , vol.11 , pp. 529-536
    • Roemer, A.1    Schwettmann, L.2    Jung, M.3
  • 42
    • 63949084246 scopus 로고    scopus 로고
    • Expression, of ADAMs ("a disintegrin and metalloprotease") in the human lung
    • Dijkstra A, Postma DS, Noordhoek JA, et al. Expression of ADAMs ("a disintegrin and metalloprotease") in the human lung. Virchows Arch. 2009;454:441-449.
    • (2009) Virchows Arch , vol.454 , pp. 441-449
    • Dijkstra, A.1    Postma, D.S.2    Noordhoek, J.A.3
  • 43
    • 33847202635 scopus 로고    scopus 로고
    • The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies
    • Dehmel T, Janke A, Hartung HP, et al. The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiol Dis. 2007;25:665-674.
    • (2007) Neurobiol Dis , vol.25 , pp. 665-674
    • Dehmel, T.1    Janke, A.2    Hartung, H.P.3
  • 44
    • 33745689524 scopus 로고    scopus 로고
    • Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness
    • Wildeboer D, Naus S, Amy Sang QX, et al. Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol. 2006;65:516-527.
    • (2006) J Neuropathol Exp Neurol , vol.65 , pp. 516-527
    • Wildeboer, D.1    Naus, S.2    Amy, S.Q.X.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.